942425-68-5
942425-68-5
Chemical Structure
PHA-767491 hydrochloride
Synonym(s): CAY-10572 hydrochloride
- CAS No.: 942425-68-5
- Formula:C12H12ClN3O
- Molecular Weight:249.70
IUPAC Name: 2-(pyridin-4-yl)-1,5,6,7-tetrahydro-4H-pyrrolo[3,2-c]pyridin-4-one hydrochloride
InChIKey: IMVNFURYBZMFDZ-UHFFFAOYSA-N
SMILES: O=C1C2=C(NC(C3=CC=NC=C3)=C2)CCN1.[H]Cl
Biological Activity: PHA-767491 hydrochloride is a dual Cdc7/Cdk9 inhibitor, with IC50s of 10 nM and 34 nM, respectively.
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
PHA-767491 hydrochloride | 99.49% | PHA-767491 hydrochloride is a dual Cdc7/Cdk9 inhibitor, with IC50s of 10 nM and 34 nM, respectively. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
CDK8-IN-1 | 98.19% | CDK8-IN-1 is a potent and selective CDK8 inhibitor with an IC50 of 3 nM. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
MK2-IN-3 hydrate | 99.08% | MK2-IN-3 hydrate (compound 16) is an orally active, selective, and ATP-competitive MAPKAP-K2 (MK-2) inhibitor with an IC50 of 8.5 nM.MK2-IN-3 hydrate is exceptional selectivity against MK-3 (IC50=0.21 μM), MK-5 (IC50=0.081 μM), ERK2 (IC50=3.44 μM), MNK1(IC50=5.7 μM) as well as CDK2, JNK2, IKK2, MSK1, and MSK2. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
VU0240382 | VU0240382 is a metabotropic glutamate receptor subtype 5 modulator whose activity differs depending on whether it has allosteric agonist activity. VU0240382 with allosteric agonist activity can activate mGlu(5) receptors in cell lines, but has no agonist activity in natural systems and has similar efficacy to mGlu(5) modulators without allosteric agonist activity in animal models. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
PARP10-IN-1 | PARP10-IN-1 is a PARP10 inhibitor with an IC50 of 1.8 μM, 2.7 μM, and >10-fold selectivity over most PARP family members, excluding PARP7 and PARP16.PARP10-IN-1 inhibits PARP10-mediated mono-ADP-ribosylation, including auto-MARylation of PARP10 and MARylation of its protein targets.PARP10-IN-1 is membrane permeable and inhibits PARP10-dependent MARylation in human embryonic kidney cells.PARP10-IN-1 can be used for the research of cancer. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
MK2-IN-3 | 99.15% | MK2-IN-3 is a potent and selective inhibitor of MAPKAP-K2 (MK-2), with an IC50 of 8.5 nM. MK2-IN-3 shows selectivity for MK-2 over MK-3, MK-5, ERK2, MNK1, p38a (IC50s=0.21, 0.081, 3.44, 5.7, and >100 μM, respectively) and MSK1, MSK2, CDK2, JNK2, IKK2 (IC50s>200 μM). MK2-IN-3 can reduce TNFα production in both U937 cells and in vivo. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
PHA-767491 | 99.97% | PHA-767491 is a dual Cdc7/Cdk9 inhibitor, with IC50s of 10 nM and 34 nM, respectively. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
PKN1/2-IN-1 | 99.92% | PKN1/2-IN-1 is a potent cell permeabilizer and selective PKN1/2 inhibitor with IC50 values of 16 nM and 210 nM for PKN1 and PKN2, respectively, and Ki values of 8 nM and 108 nM, respectively. PKN1/2-IN-1 exhibits strong intracellular PKN2 binding capacity in NanoBRET assays (IC50 = 2.1 μM). PKN1/2-IN-1 can be used to study physiological processes such as tumor cell migration. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
2-(Pyridin-4-yl)terephthalic acid | 2-(Pyridin-4-yl)terephthalic acid (6-(4-Pyridyl)terephthalic acid) is a metal-organic framework (MOF). | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Win 47338 | Win 47338 (compound 14) is a control compound of inhibitors of the mitotic kinase monopolar spindle MPS1 and Aurora kinases (AurA/AurB) (Ki>100 μM). | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
[4,2':6',4''-Terpyridine]-4'-carboxylicacid | [4,2':6',4''-Terpyridine]-4'-carboxylicacid is a metal-organic framework (MOF). | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
